<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02976077</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A01271-50</org_study_id>
    <nct_id>NCT02976077</nct_id>
  </id_info>
  <brief_title>RC2S+: Remediation of Social Cognitive Impairments</brief_title>
  <acronym>RC2S+</acronym>
  <official_title>Preliminary Validation of the RC2S+ Therapy in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital le Vinatier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital le Vinatier</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Difficulties in social interactions are a central characteristic of people with&#xD;
      schizophrenia, and can be partly explained by impairments of social cognitive processes.&#xD;
      According to renown researchers, three to five social cognitive processes are usually altered&#xD;
      in schizophrenia: (1) emotional processing; (2) theory of mind (ToM); (3) attributional&#xD;
      style; and (4 and 5) social perception and knowledge. The components of social cognition&#xD;
      appear to be related to both symptomatology and functioning in everyday life.&#xD;
&#xD;
      New strategies of cognitive remediation have been recently developed to target these deficits&#xD;
      and few meta analyses have assessed the extent to which social cognitive remediation programs&#xD;
      have led to multiple improvements for schizophrenia patients. Overall, it seems that such&#xD;
      therapies showed encouraging results in both patient interest and motivation, and social&#xD;
      cognitive processes.&#xD;
&#xD;
      The RC2S therapy is the first individualized and partly computerized program through which&#xD;
      patients practice social interactions and develop social cognitive abilities with simulation&#xD;
      techniques in a realistic environment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods:&#xD;
&#xD;
      This is a randomized controlled trial to establish the validity of the RC2S+ program in&#xD;
      schizophrenia.&#xD;
&#xD;
      The project's main objective is to assess the impact of RC2S+ on social cognitive impairments&#xD;
      in schizophrenia compared with a cognitive remediation program (control therapy) focusing on&#xD;
      neurocognition, equivalent in terms of number, duration and rhythm of sessions.&#xD;
&#xD;
      The study has four other objectives:&#xD;
&#xD;
        1. To assess the influence of the RC2S+ therapy versus control therapy on neurocognitive&#xD;
           processes&#xD;
&#xD;
        2. To assess the impact of the RC2S+ therapy versus control therapy on social functioning&#xD;
&#xD;
        3. To assess the impact of the RC2S+ therapy versus control therapy on both positive and&#xD;
           negative symptoms&#xD;
&#xD;
        4. To study the maintenance of benefits 3 months forward&#xD;
&#xD;
      Outcomes:&#xD;
&#xD;
      To treat social cognitive impairments in people with schizophrenia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 29, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the HB (Hostility Bias) score</measure>
    <time_frame>week 12</time_frame>
    <description>AIHQ (Ambiguous Intentions Hostility Questionnaire)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in social cognitive</measure>
    <time_frame>week 12</time_frame>
    <description>ACSO ( Self-Assessment Scale of Social Cognition Disorders)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in episodic verbal learning and memory</measure>
    <time_frame>week 12</time_frame>
    <description>CVLT( California Verbal Learning Test),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in visual attention and task switching</measure>
    <time_frame>week 12</time_frame>
    <description>TMT( Trial Making Test)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in social functioning</measure>
    <time_frame>week 12</time_frame>
    <description>FEFSF (First Episode Social Functioning Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in symptoms at week 12</measure>
    <time_frame>week 12</time_frame>
    <description>PANSS (Positive And Negative Symptoms Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in visuospatial abilities at week 12</measure>
    <time_frame>week 12</time_frame>
    <description>TMT( Trial making Test)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in executive functioning at week 12</measure>
    <time_frame>week 12</time_frame>
    <description>FNART(French National Adult reading Test)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>RC2S+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RC2S+&#xD;
Preparation sessions (sessions 1 &amp; 2):&#xD;
Functional Outcomes Scale - Social Cognition (ERF-CS)&#xD;
Psychoeducation about social cognitive impairments&#xD;
Concrete objectives&#xD;
Cognitive remediation (sessions 3 to 22):&#xD;
Paper-and-pencil session&#xD;
Simulation session&#xD;
Home-based task&#xD;
Transfer sessions (sessions 23 &amp; 24):&#xD;
Transfer of skills in dayly life - generalization&#xD;
Assessment of the achievement of objectives</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control therapy&#xD;
Preparation sessions (sessions 1 &amp; 2):&#xD;
Functional Outcomes Scale - Neurocognition&#xD;
Psychoeducation about cognitive impairments&#xD;
Concrete objectives&#xD;
Cognitive remediation (sessions 3 to 24):&#xD;
Paper-and-pencil session&#xD;
Simulation session&#xD;
Home-based task</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>RC2S+</intervention_name>
    <description>new cognitive remediation program</description>
    <arm_group_label>RC2S+</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>active comparator</intervention_name>
    <description>cognitive remediation program</description>
    <arm_group_label>Control therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18-45 years old&#xD;
&#xD;
          -  Diagnosis of schizophrenia assessed with DSM5 criteria (APA, 2013)&#xD;
&#xD;
          -  No modification of psychotropic treatment during the month before inclusion (variation&#xD;
             of 20% of the dose is tolerated&#xD;
&#xD;
          -  French native language or education in a French school since the first year of primary&#xD;
             school&#xD;
&#xD;
          -  Consent to participate to the study and agreement of the legal guardian&#xD;
&#xD;
          -  Patients who have not benefited from cognitive remediation during the three months&#xD;
             before inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Substance use disorder (criteria of DSM-5), except for caffeine and tobacco&#xD;
&#xD;
          -  Neurologic disorders (vascular, infectious or neurodegenerative)&#xD;
&#xD;
          -  Uncorrected visual deficit&#xD;
&#xD;
          -  Medical drugs with cerebral or psychological effect (e.g, corticosteroids)&#xD;
&#xD;
          -  Patients resistant to antipsychotic medication&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>FRANCK NICOLAS, PUPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>LE VINATIER HOSPITAL BRON FRANCE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>centre de réhabilitation - Hôpital le Vinatier</name>
      <address>
        <city>Lyon</city>
        <state>Rhône</state>
        <zip>69006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 16, 2016</study_first_submitted>
  <study_first_submitted_qc>November 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>social cognition</keyword>
  <keyword>cognitive remediation</keyword>
  <keyword>emotions</keyword>
  <keyword>theory of mind</keyword>
  <keyword>attributions</keyword>
  <keyword>social perception</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

